Associate Professor Mary Bebawy has a PhD in Pharmacy (University of Sydney) and is currently the Head of the Laboratory of Cancer Cell Biology and Therapeutics in the Graduate School of Health at the University of Technology Sydney.
She has an active research portfolio focusing on the molecular basis of cancer relapse. She is an internationally recognized cancer researcher and pharmaceutical scientist with a background in commercial research and development.
Associate Professor Bebawy’s team were the first to discover the role of extracellular vesicles in the spread of cancer multidrug resistance.
Associate Professor Bebawy and her team were also the first to also discover that extracellular vesicles can re-template the proteome and transcriptome of cancer cells to ensure the transfer and dominance of cancer traits within cell populations.These findings have since been translated clinically with her team discovering the utility of extracellular vesicles as a prognostic in Myeloma.
Her national and international standing has been recognised on numerous occasions, including an invitation by “Women in Science Australia” to showcase her achievements as part of activities to promote research excellence in Australia.